AirXpanders is a medical device company that has developed the AeroForm tissue expander. AeroForm is a patient controlled breast tissue expander for reconstructive surgeries such as breast reconstruction after mastectomy. Co-investors include GBS Venture Partners, Heron Capital, Prolog Ventures, and Vivo Ventures. In June 2015, AirXpanders went public (AXP:ASE).
Annexon Biosciences is developing therapeutic products that halt the progression of complement-mediated neurodegeneration. Co-investors include Clarus Ventures, New Enterprise Associates, Novartis, and Stanford University.
Arista MD offers a customized referral management system to meet the needs of primary and specialty care physicians while significantly reducing costs in “inappropriate” referrals. Co-investors include Avalon Ventures.
CareWell Urgent Care
CareWell Urgent Care is establishing and operating urgent care centers in the New England area. Co-investors include CHL Medical Partners.
Flex Pharma is developing novel treatments for muscle cramps and spasms by halting repetitive firing of motor neurons. Co-investors include include Bessemer Venture Partners, Founders Fund, Lightstone Ventures, and Longwood Venture Partners. In January 2015, Flex Pharma went public (NASDAQ: FLKS).
Galera Therapeutics is developing biopharmaceuticals targeting oxygen metabolic pathways to treat mucositis, fibrosis, and cancer. Co-investors include New Enterprise Associates, and Novartis Venture Fund.
Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Co-investors include Abingworth, HBM Partners, and InterWest.
Intervene is a catheter-based technology to create native vein valves in the lower leg to treat severe systems associated with deep vein valve failure. Co-investors include Launch Capital and Rivervest Partners.
Lemonaid Health is leading a second wave of telehealth where technology algorithms power quality care. Lemonaid leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumer for less than typical co-pays. Lemonaid is focused on creating a revolutionized patient experience and improving and optimizing clinical care through the advancements in machine learning and AI. Co-Investors include Adaptive Healthcare Fund, 415 Ventures, Hikma Ventures, Novartis Venture Fund, and Vega Ventures.
Mirna Therapeutics is developing replacement therapy for cancer treatment by harnessing the power of tumor suppressor miRNAs to kill cancer cells. Co-investors include New Enterprise Associates, Pfizer Venture Investments, Soffinova Ventures, and Osage University Partners. In October 2015, Mirna Therapeutics went public. (NASDAQ: MIRN)
Powervision has developed the FluidVision® intraocular lens implant, designed to restore the vision of those affected by presbyopia and/or cataracts. Co-investors include Aisling Capital, ATV, Frazier Healthcare Ventures, and Venrock. Aquired by Alcon in 2019.
RQx is discovering and developing novel broad-spectrum antibiotics. Co-investors include Avalon Ventures.
Gene therapy based pharmaceuticals for veterinary applications. Co-investors include Frazier Healthcare Ventures and Adage Capital.
Spirox is developing a minimally-invasive treatment for nasal valve collapse.Co-investors include Aperture Ventures, Western Technology Investments, and Venrock.
SynthoRX is advancing the breakthrough technology of synthetic DNA bases that can be replicated in vivo for numerous medical and technological applications. Co-investors include Avalon Ventures. In December 2018, SynthroRX went public (NASDAQ: THOR).